Pradaxa
Stroke crisis to hit UK unless government acts, warns report
December 5, 2011Sales and Marketing BMS, Pfizer, Pradaxa, UK, stroke
Major improvements are needed in the treatment of atrial fibrillation to avoid a UK stroke epidemic, according to a new …
NICE U-turn on Boehringer’s Pradaxa
November 1, 2011Sales and Marketing NICE, Pradaxa
NICE is now recommending Boehringer Ingelheim’s Pradaxa for stroke prevention after initially rejecting the drug on cost-effectiveness issues. NICE has …
Boehringer agrees Pradaxa kidney function warning
October 30, 2011Sales and Marketing AF, EMA, Pradaxa, renal function
Boehringer Ingelheim is to alert doctors in Europe of the need to check patients’ kidney function before prescribing anticoagulant Pradaxa. …
Eliquis launched in the UK
September 19, 2011Sales and Marketing Eliquis, Pradaxa, VTE, Xarelto
Eliquis, the latest entrant to the competitive oral anticoagulant market, has been launched in the UK.Co-developed and co-marketed by Pfizer …
Pradaxa and Eliquis gain trial boost over warfarin
August 31, 2011Sales and Marketing Eliquis, Pradaxa, Xarelto, apixaban
A pair of new blood thinners are superior to warfarin when it comes to reducing the risk of stroke in …
NICE wants more information on Pradaxa
August 17, 2011Sales and Marketing NICE, Pradaxa
NICE has asked for more information on Pradaxa, after deciding in preliminary guidance that the drug is not cost-effective in …
Pradaxa approved for stroke prevention in Europe
August 9, 2011Sales and Marketing Pradaxa, atrial fibrillation, direct thrombin inhibitor
Boehringer Ingelheim’s Pradaxa has become the first drug in 50 years to be approved in Europe for stroke prevention in …
Xarelto receives FDA approval
July 4, 2011Sales and Marketing Bayer, Eliquis, Johnson & Johnson, Pradaxa, Xarelto, anticoagulant
Bayer and Johnson & Johnson’s oral blood thinner Xarelto has been approved in the US for the prevention of deep …
Boehringer’s Pradaxa recommended for expanded European licence
April 18, 2011Sales and Marketing Boehringer Ingelheim, CHMP, Pradaxa
Pradaxa is on course to expand its European licence with a recommendation from the CHMP for a new indication in …
Boehringer bets on Pradaxa to fill portfolio gaps
April 6, 2011Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa
Boehringer Ingelheim has identified Pradaxa as one of the cornerstones of its “new growth phase” as the manufacturer seeks to …
Merck drops oral anticoagulant
March 25, 2011Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar
Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …
Companies join forces to promote AF awareness
February 16, 2011Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation
Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
FDA approves Boehringer’s Pradaxa
October 20, 2010Sales and Marketing Boehringer, Pradaxa, atrial fibrilation
Boehringer Ingelheim’s Pradaxa has stolen a march over its rivals by being the first new oral anticoagulant to reach the …
FDA committee backs Pradaxa
September 23, 2010Sales and Marketing Boehringer, Pradaxa, atrial fibrilation
An FDA committee has voted unanimously in favour of approving Pradaxa for stroke prevention in patients with atrial fibrillation. The …
